A neurological network that may predict patients with Parkinson's disease that are likely to have a favorable response to sham surgery has been identified by scientists.
Parkinson's disease is the second most common neurological disorder, affecting almost 10 million people worldwide. While there is no cure for this disease, many patients are able to successfully manage their symptoms. Surgical interventions appear to provide relief for some patients.
Unfortunately, these procedures have been difficult to fully evaluate because many patients have a strong placebo response to sham surgery in clinical trials. David Eidelberg and colleagues at the Feinstein Institute for Medical Research evaluated Parkinson's disease patients enrolled in a double blind gene therapy trial. Brain networks were evaluated prior to the sham surgery and after recovery.